European Gram Negative AntiBacterial Engine
ENABLE
Industry and research organisations with interesting molecules and programmes can join the ENABLE project as partners and work with a diverse range of experts in microbiology, pharmacology and chemistry to help advance their molecule through the drug development process until it is an attractive candidate for clinical testing.
Please note that due to ENABLE ending very soon we are not accepting Expressions of Interest (EoIs) anymore.
Eligibility
Organisations within the European Union that are eligible may submit a three-page Expression of Interest to the ENABLE project with details of their anti-infective programmes that meet - or have the potential to meet - project entry thresholds. Below - in the document section - you can find information on the key thresholds, the EoI template and the open call protocol.
Key thresholds:
For hit to lead project entry
For lead to candidate project entry
Earlier stage programmes may not have generated full data in line with thresholds established by the ENABLE program. However, applications are still encouraged as the ENABLE programme may be able to support highly promising programmes with incomplete data.
How to submit an EoI?
Please note that due to ENABLE ending very soon we are not accepting Expressions of Interest (EoIs) anymore.
The ENABLE team is pleased to support all EoIs during their development and will give feedback on potential data missing or content/layout that will improve the application. It will not comment upon the data itself. The EoI should be no longer than three pages and contain non-confidential information (structures may be omitted). Once submitted, your EoI will be assessed for fit to project thresholds and level of potential by two expert independant reviewers. This process will typically take 2 weeks.
You will then be contacted by the ENABLE team with feedback and the next step for the programme,
- whether that is a request for further data,
- feedback on eligibility,
- or an invitation to discuss your programme under CDA, with a view to full presentation to the Porfolio Mangement Committee.
Following your submission of an EoI to ENABLE, what happens next?
Tel: 0049 (0)30-264 921-58
Tel: 0049 (0)30-264 921-58
Email: [email protected]
The research leading to these results has received support from the Innovative Medicine Initiative Joint Undertaking under grant agreement no 115583, resources of which are composed of financial contributions from the European Union`s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies` in kind contribution.